Annals of Cancer Research and Therapy
Online ISSN : 1880-5469
Print ISSN : 1344-6835
ISSN-L : 1344-6835
Pancreatic Neuroendocrine Tumors: Experience of a Tertiary Care Center in Lebanon
Sally TemrazMohamad HaidarRita AssiAyman HakimElio JabraMaya CharafeddineIbrahim El HalabiDeborah MukherjiAli Shamseddine
Author information
JOURNALS FREE ACCESS

2020 Volume 28 Issue 1 Pages 9-15

Details
Abstract

Background/Aims: Pancreatic neuroendocrine tumors (p-NETs) are a group of functionally and biologically heterogeneous tumors which are clinically rare. Here we report the clinical features, treatment strategies and survival of p-NET patients treated at a single institution.

Methods: Patients pathologically diagnosed with p-NETs and treated at The American University of Beirut Medical Center between 2005 and 2015 were recruited. Tissue specimens from patients’ samples were collected during surgical resections and needle biopsies performed at our center to determine tumor characteristics. The 2010 WHO NET and ENETs classification systems were used in concordance for all cases to determine staging. The WHO divided the p-NET grades into: Grade 1 neuroendocrine tumors (G1), Grade 2 neuroendocrine tumors (G2), Grade 3 neuroendocrine carcinoma (G3) and mixed adeno and neuroendocrine carcinoma (MANEC). Survival analyses using Kaplan-Meier were plotted using SPSS 23.0 (IBM).

Results: We identified 27 p-NET patients with pathological reports. Median age of patients at diagnosis was 52 years. The majority were males (63%). The proportions of patients with pathologic TNM stages IA/B, IIA/B, III, and IV disease were 18%, 22%, 4%, and 56% of all patients. Seventeen patients (63%) underwent surgery and eighteen patients (67%) received chemotherapy and/or somatostatin analogues. Median survival of the whole cohort was more than 10.8 years while the median survival of patients diagnosed at stage IV was 6 years. The one and two-year survival rates for the entire cohort were 97% and 83%, respectively. The one and two-year survival rates of stage IV were 93% and 70%, respectively.

Conclusion: Because of their variable presentations and non-standardized treatment plans, p-NETs still represent a significant clinical challenge and their management requires a coordinated multidisciplinary approach.

Information related to the author
© 2020 by The Japanese Society of Strategies for Cancer Research and Therapy
Previous article Next article
feedback
Top